NCT07220512Recruiting
The Better, Harder, Faster, Stronger Study
The BHFS Study (Better, Harder, Faster, Stronger): Does Neoadjuvant Chemotherapy Improve Fitness for Surgery?
Source: ClinicalTrials.gov · Last updated 15 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate changes in the electronic Frailty Index (eFI) score following 3-4 cycles of neoadjuvant chemotherapy (NACT) in participants with advanced ovarian and endometrial cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 35 (estimated)
- First submitted
- 13 Oct 2025
- Start date
- 28 Jul 2025
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Endometrial cancer, Ovarian cancer
- NCT number
- NCT07220512
What you commit to
- Study type: Observational
- Planned participants: 35
- From 28 Jul 2025 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of poorly controlled psychiatric conditions, defined as hospitalization within the prior 3 months for psychiatric disorders, traumatic brain injury, cerebrovascular event, or dementia, per the enrolling investigator.
Other illness
- History of brain metastases.
- Use of anti-amyloid agents, cholinesterase inhibitors, or Memantine for Alzheimers/cognitive impairment, at the time of enrollment.
- Vision impairment that would impede completion of study assessments, per enrolling investigator.
Who the study is looking for
- Ability to understand and willingness to sign an IRB-approved informed consent.
- Age \> 55 years at the time of enrollment.
- Newly diagnosed suspected ovarian/primary peritoneal/fallopian tube carcinoma of any histological subtype, FIGO Stage II-IV, per enrolling investigator, or newly diagnosed suspected endometrial carcinoma of any histologic subtype, FIGO Stage II-IV, per enrolling investigator.
- Planned for 3 or 4 cycles of NACT, with interval cytoreductive surgery planned thereafter.
- Ability to read, understand, and write the English language.
- As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study.
Age in the registry: 55 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wake Forest Baptist Comprehensive Cancer Center Coordinator of this site? Confirm its status | Winston-Salem | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.